Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.

NCT05957536 is registered in ClinicalTrials.gov with D3 Bio (Wuxi) Co., Ltd as lead sponsor.

NCT NCT05957536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05957536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 19, 2023
Completion date
December 19, 2028
Enrollment
128 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive advanced solid tumors